Effectiveness of metronomic chemotherapy (MCT) with losartan (LOS) and with (CY) in the M-406 triple negative mammary adenocarcinoma model in female mice with metabolic syndrome (Mets)

HILLOTTE G, ; FAZZI A, ; CORONEL C, ; LANZILLOTTA M, ; BARRANCO MM, ; SCHAROVSKY OG, ; RICO MJ, ; ROZADOS VR, ; GARCÍA F, ; MAINETTI LE

Congreso; Reunión conjunta SAIC, SAI, AAFE, NANOMER.AR; 2021

Metabolic Syndrome is a pathology that frequently coexists with breast cancer and can worsens cancer prognosis. This situation must be considered when choosing a correct cancer treatment. Our aim was to evaluate the effectiveness and toxicity of MCT with CY+LOS in mice with MetS bearing a mammary adenocarcinoma, and its effect on the tumor micro environment (TME). CBi female mice (5 weeks) were fed with a diet with 40% calories of fat (HFD) throughout the experiment. At 20 weeks, the development of MetS was confirmed by biochemical and morphological parameters. Once the MetS features were settled, mice were challenged orthotopically with M-406 tumor (day 0); when the tumor was palpable, mice were distributed into 4 groups, GI: Control, with no treatment; GII: Cy 25mg/kg/day in the drinking water; GIII: Los 150mg/kg/day in the drinking water; GIV: Treated as GII + GIII. Mice were weighted and tumor volume measured 3 times/week. When tumors were exponentially growing, mice were euthanized, tumors excised and used for immunohistochemistry (IHC). On day 19, GIV showed tumor growth inhibition compared to GI (P